Investing.com - LAVA Therapeutics NV reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
LAVA Therapeutics NV announced earnings per share of $-0.31 on revenue of $468K. Analysts polled by Investing.com anticipated EPS of $-0.6002 on revenue of $500K.
LAVA Therapeutics NV shares are down 72% from the beginning of the year and are trading at $2.46 , down-from-52-week-high.
LAVA Therapeutics NV follows other major Healthcare sector earnings this month
LAVA Therapeutics NV's report follows an earnings beat by Medtronic on August 23, who reported EPS of $1.13 on revenue of $7.37B, compared to forecasts EPS of $1.12 on revenue of $7.22B.
Merck ADR had beat expectations on Friday with third quarter EPS of $0.5392 on revenue of $5.69B, compared to forecast for EPS of $0.5165 on revenue of $5.57B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar